Mark Johnson

2.5k citations

53 papers · 1.8k indexed · h-index 22

Impact in

Cardiology and Cardiovascular Medicine top 2%
- Cardiac Valve Diseases and Treatments
Hepatology top 5%
- Hepatitis C virus research

Papers in ⓘ

Virology 10
- HIV Research and Treatment 10
Infectious Diseases 21
- HIV/AIDS drug development and treatment 21
- HIV/AIDS Research and Interventions 9

Co-authors: Ronen Gurvitch (4 shared papers)John G. Webb (4 shared papers)Namal Wijesinghe (3 shared papers)Fabian Nietlispach (3 shared papers)Christopher Thompson (3 shared papers)David Wood (3 shared papers)Jian Ye (3 shared papers)Jonathon Leipsic (3 shared papers)
Journals: British Journal of Clinical Pharmacology (7 papers)JACC: Cardiovascular Interventions (3 papers)European Journal of Clinical Pharmacology (3 papers)Antimicrobial Agents and Chemotherapy (3 papers)Pharmacology Research & Perspectives (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Mark Johnson

52 papers receiving 1.7k citations

Peers

Countries citing papers authored by Mark Johnson

Since Specialization

Citations

This map shows the geographic impact of Mark Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Johnson more than expected).

Fields of papers citing papers by Mark Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Johnson. The network helps show where Mark Johnson may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Johnson Line = papers co-authored together Mark Johnson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Transcatheter Valve-in-Valve Implantation for Failed Bioprosthetic Heart Valves Circulation ·John G. Webb, David Wood, Jian Ye, Ronen Gurvitch, Jean‐Bernard Masson, Josep Rodés‐Cabau, Mark Osten, Eric Horlick, Olaf Wendler, Éric Dumont, Ronald G. Carere, Namal Wijesinghe, Fabian Nietlispach, Mark Johnson, Christopher Thompson, Robert Moss, Jonathon Leipsic, Brad Munt, Samuel V. Lichtenstein, Anson Cheung	2010	345
2	Early Detection of Viral Resistance by Determination of Hepatitis B Virus Polymerase Mutations in Patients Treated by Lamivudine for Chronic Hepatitis B Hepatology ·Si Nafa Si Ahmed, David Tavan, Christian Pichoud, Françoise Berby, Lieven Stuyver, Mark Johnson, Philippe Merle, Hassane Abidi, C. Trépo, Fabien Zoulim	2000	176
3	Aortic Annulus Diameter Determination by Multidetector Computed Tomography JACC: Cardiovascular Interventions ·Ronen Gurvitch, John G. Webb, Ren Yuan, Mark Johnson, Cameron Hague, Alexander B. Willson, Stefan Toggweiler, David Wood, Jian Ye, Robert Moss, Christopher Thompson, Stephan Achenbach, James K. Min, Troy LaBounty, Ricardo C. Cury, Jonathon Leipsic	2011	142
4	Multislice Computed Tomography for Prediction of Optimal Angiographic Deployment Projections During Transcatheter Aortic Valve Implantation JACC: Cardiovascular Interventions ·Ronen Gurvitch, David Wood, Jonathon Leipsic, Edgar Tay, Mark Johnson, Jian Ye, Fabian Nietlispach, Namal Wijesinghe, Anson Cheung, John G. Webb	2010	106
5	Transcatheter Closure of Paravalvular Defects Using a Purpose-Specific Occluder JACC: Cardiovascular Interventions ·Fabian Nietlispach, Mark Johnson, Robert R. Moss, Namal Wijesinghe, Ronen Gurvitch, Edgar Tay, Christopher Thompson, John G. Webb	2010	91
6	Factors contributing to an increase in duplicate medication order errors after CPOE implementation Journal of the American Medical Informatics Association ·Tosha B. Wetterneck, James M. Walker, Mary Ann Blosky, Randi Cartmill, Peter Hoonakker, Mark Johnson, Evan Norfolk, Pascale Carayon	2011	88
7	Characterising the complexity of medication safety using a human factors approach: an observational study in two intensive care units BMJ Quality & Safety ·Pascale Carayon, Tosha B. Wetterneck, Randi Cartmill, Mary Ann Blosky, Roger Brown, Robert Kim, Sandeep Kukreja, Mark Johnson, Bonnie Paris, Kenneth E. Wood, James M. Walker	2013	75
8	Analysis of the distribution of erythrocyte sodium lithium countertransport in a sample representative of the general population Genetic Epidemiology ·Eric Boerwinkle, Stephen T. Turner, Richard Weinshilboum, Mark Johnson, Elliott Richelson, Charles F. Sing, D. C. Rao	1986	64
9	Washout periods for brimonidine 0.2% and latanoprost 0.005% American Journal of Ophthalmology ·William C Stewart, Keri T Holmes, Mark Johnson	2001	54
10	Sodium-lithium countertransport and blood pressure in healthy blood donors. Hypertension ·S. T. Turner, Mark Johnson, Eric Boerwinkle, Elliott Richelson, Howard F. Taswell, Charles F. Sing	1985	50
11	Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment European Journal of Clinical Pharmacology ·S Weller, Julie Borland, Shuguang Chen, Mark Johnson, Paul Savina, Brian Wynne, Toshihiro Wajima, Amanda Peppercorn, Stephen C. Piscitelli	2013	48
12	Pharmacokinetics of Zidovudine and Lamivudine in Neonates following Coadministration of Oral Doses Every 12 Hours The Journal of Clinical Pharmacology ·Dhayendre Moodley, Kubendran Pillay, Kimesh Naidoo, Jagidesa Moodley, Mark Johnson, Katy H. P. Moore, Paul N. Mudd, Gary E. Pakes	2001	48
13	Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis British Journal of Clinical Pharmacology ·Mark Johnson, Gert A. Verpooten, M J Daniel, Robert S. Plumb, Jonathan Moss, D. Van Caesbroeck, Marc E. De Broe	1998	47
14	Lumbar vertebral stress injuries in fast bowlers: A review of prevalence and risk factors Physical Therapy in Sport ·Mark Johnson, Manuela L. Ferreira, Julia M. Hush	2011	46
15	The pharmacokinetics of lamivudine in patients with impaired hepatic function European Journal of Clinical Pharmacology ·Mark Johnson, Jiří Horák, Peter Breuel	1998	30
16	15-Second conducted electrical weapon exposure does not cause core temperature elevation in non-environmentally stressed resting adults Forensic Science International ·Donald M. Dawes, Jeffrey D. Ho, Mark Johnson, Erik J. Lundin, Timothy A. Janchar, James R. Miner	2008	29
17	EHR‐related medication errors in two ICUs Journal of Healthcare Risk Management ·Pascale Carayon, Shimeng Du, Roger Brown, Randi Cartmill, Mark Johnson, Tosha B. Wetterneck	2017	29
18	Impact of conducted electrical weapons in a mentally ill population: a brief report The American Journal of Emergency Medicine ·Jeffrey D. Ho, Donald M. Dawes, Mark Johnson, Erik J. Lundin, James R. Miner	2007	25
19	Medication Safety in Two Intensive Care Units of a Community Teaching Hospital After Electronic Health Record Implementation: Sociotechnical and Human Factors Engineering Considerations Journal of Patient Safety ·Pascale Carayon, Tosha B. Wetterneck, Randi Cartmill, Mary Ann Blosky, Roger Brown, Peter Hoonakker, Robert Kim, Sandeep Kukreja, Mark Johnson, Bonnie Paris, Kenneth E. Wood, James M. Walker	2017	24
20	Sodium-lithium countertransport in ambulatory hypertensive and normotensive patients. Hypertension ·Stephen T. Turner, Eric Boerwinkle, Mark Johnson, Elliott Richelson, Charles F. Sing	1987	24

About Mark Johnson

Mark Johnson is a scholar working on Virology, Infectious Diseases, Health Information Management, Hepatology and Emergency Medical Services, having authored 53 papers that have together received 1.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (10 papers), HIV/AIDS Research and Interventions (9 papers), Hepatitis C virus research (6 papers), Electronic Health Records Systems (4 papers), Patient Safety and Medication Errors (4 papers), Infective Endocarditis Diagnosis and Management (4 papers) and Cardiac Valve Diseases and Treatments (4 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (716 citations), Hepatology (238 citations), Virology (131 citations), Geriatrics and Gerontology (107 citations) and Medical Laboratory Technology (40 citations). Mark Johnson has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Ronen Gurvitch, John G. Webb, Namal Wijesinghe, Fabian Nietlispach, Christopher Thompson, David Wood, Jian Ye, Jonathon Leipsic, Anson Cheung and Robert Moss. Their work appears in journals such as British Journal of Clinical Pharmacology, JACC: Cardiovascular Interventions, European Journal of Clinical Pharmacology, Antimicrobial Agents and Chemotherapy and Pharmacology Research & Perspectives.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact